In addition to CD22ΔE12, CD22 exon 2 (CD22E2) skipping that results in very low CD22E2 mRNA levels also occurs in B-ALL and is associated with resistance to CD22-directed immunotherapies due to reduced expression of the target CD22 protein. The gene discussed is CD22; the disease is precursor B-cell acute lymphoblastic leukemia.